Objectives To compare the epidemiological and clinical characteristics, management, and outcome of intussusception in children in the southern and western states in India. Methods This multicenter observational study, conducted in 21 hospitals between August 2019 and December 2022, compared the characteristics of intussusception among children younger than 2 y hospitalized with intussusception in the southern (Kerala and Karnataka) and western (Maharashtra and Gujarat) states in India. Children were diagnosed with intussusception according to level 1 Brighton Collaboration criteria. Results Of the 1,319 children enrolled, 860 (65.2%) and 459 (34.8%) were from the southern and western states, respectively. Clinical manifestations were similar in both regions; however, children from the southern states exhibited more frequent incessant crying (32.2% vs. 1.3%; p < 0.001). The predominance of ileo-colic presentation was significantly more marked in the southern states vs. the western states (91.7% vs. 80.6%; p < 0.001). Significantly more cases were resolved by radiological reduction in the southern states (89.2% vs. 56.9%; p < 0.001), whereas surgical intervention was more common in the western states. The case fatality rate was 0.3%. All four deaths occurred in the western states (p = 0.022). Conclusions The poorer outcome in the western states might be attributable to longer delays in seeking treatment, and disparities in healthcare access. These regional divergences highlight the differences in healthcare infrastructure, and socioeconomic inequities between regions. Managing these differences through health education, improving access to diagnostic tools, and timely intervention could reduce the burden of intussusception in India.
Section Objectives Immunization with conventional rotavirus vaccines (RVVs) has been reported to intensify the risk of intussusception (IS). However, the risk of IS following vaccination with the recently introduced ROTASIIL is not clearly understood. The aim of this study was to describe the clinical and epidemiological profile of IS among children after vaccination with RVV. AbstractSection Methods A hospital-based multicenter observational study was carried out at five private medical college-based tertiary care hospitals in Karnataka, India, over a 30-mo period. Children younger than 2 y admitted with confirmed IS were enrolled. Data were collected on demographics, clinical features, and vaccination history. AbstractSection Results Of 196 children with confirmed IS, 153 (78%) had received ROTASIIL. The median age (interquartile range [IQR]) of the participants was 9 (6–14) mo, and 69% were male. The median age (IQR) at receiving first, second, and third dose of RVV was 7 (6–9) wk, 12 (11–14) wk, and 17 (16–20) wk, respectively. Of the participants, 91.8% had ileo-colic IS and the IS was resolved by imaging-guided reduction in 78.6%. Two, three, and eleven cases of IS were reported within 21 d after receiving the first, second and third dose of RVV, respectively. AbstractSection Conclusions This study provides baseline epidemiological data on IS among children younger than 2 y. Although, no definite association between ROTASIIL and IS was noted, this study provides health authorities with information on the risks and benefits of ROTASIIL in a real-world setting.
ROTASIIL®, a pentavalent oral rotavirus vaccine licensed in India in 2017, was introduced into the Universal Immunization Program in 2018. Primary endpoint was vaccine effectiveness (VE) against moderate and severe rotavirus gastroenteritis (RVGE) in children <2 years using pooled data from two multi-center observational studies across 32 hospitals in seven states (July 2019–December 2023). A test-negative case–control design estimated adjusted VE (aVE) for three ROTASIIL® doses. Among 2,243 children aged 3–23 months hospitalized with acute gastroenteritis, 638 were ELISA-positive. For completed series (three doses), the aVE against hospitalization due to RVGE among children aged 3–23 months was 52% (95% CI, 32–66), with the highest aVE of 88% (CI, 53–97) observed among those aged 3-5 months. The aVE against moderate RVGE was 56% (CI, 11-79), and that of severe RVGE was 54% (CI, 31-70). The highest genotype-specific aVE was 62% (CI, 29-80) against G1P[8]. For at least one dose, the aVE was 45% (CI, 26–60) among children aged 1–23 months. A completed series of ROTASIIL® effectively reduced RVGE hospitalizations especially with a higher VE observed in younger age groups, suggesting the benefits of timely immunization.